Chemotherapy of advanced gastric cancer.

[1]  R. Berardi,et al.  Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  L. Schwartz,et al.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Hollerbach,et al.  A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) , 2006 .

[5]  A. Norman,et al.  Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Serve,et al.  Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. , 2006, World journal of gastroenterology.

[8]  J. Ajani,et al.  Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Takayama,et al.  Phase I/II study of docetaxel, CDDP and S-1 in unresectable advanced gastric cancer , 2005 .

[10]  L. Assersohn,et al.  Phase II trial evaluating capecitabine and irinotecan in patients (pts) with esophago-gastric (E-G) carcinoma having progressed or relapsed within 3 months of platinum-based chemotherapy , 2005 .

[11]  E. Cho,et al.  Randomized phase II trial of taxanes plus 5-fluorouracil for advanced gastric cancer , 2005 .

[12]  D. Heo,et al.  Phase II study of low-dose paclitaxel and cisplatin as second-line therapy in 5-fluorouracil and platinum pretreated gastric cancer , 2005 .

[13]  B. Ryoo,et al.  Oxaliplatin and capecitabine combination chemotherapy for patients with advanced gastric carcinoma: A pilot study results , 2005 .

[14]  T. Rice,et al.  Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer , 2005 .

[15]  B. Dörken,et al.  Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study , 2005 .

[16]  N. Foster,et al.  Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia: A phase II study from the North Central Cancer Treatment Group , 2005 .

[17]  J. Roh,et al.  Fractional weekly administration of irinotecan and cisplatin as a second-line treatment for advanced gastric cancer , 2005 .

[18]  R. Salazar,et al.  Phase I trial of cisplatin (CDDP), docetaxel (TXT) and CPT-11 in patients (p) with advanced esophagogastric cancer: Feasibility and activity related to XPD and UGT1A1 gene polymorphisms , 2005 .

[19]  M. Basso,et al.  Docetaxel and oxaliplatin combination as second-line treatment in patients with advanced gastric cancer , 2005 .

[20]  H. Song,et al.  Phase II study of biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer , 2005 .

[21]  F. Lordick,et al.  Oxaliplatin plus 5FU/folinic acid (FUFOX regimen) in 1st line metastatic gastric cancer (MGC). Results of the Multicenter Phase II STOMOX Trial , 2005 .

[22]  J. Zaluski,et al.  Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients , 2005 .

[23]  F. Ciardiello,et al.  Phase II study of weekly docetaxel and capecitabine in patients with metastatic gastric cancer (GC) , 2005 .

[24]  J. Ajani,et al.  Multi-center phase II study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC) , 2005 .

[25]  M. Stauch,et al.  Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study , 2005 .

[26]  B. D. Park.  Seiberg-Witten invariants and branched covers along tori , 2005 .

[27]  Toshiharu Yamaguchi,et al.  A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. , 2005, Anticancer research.

[28]  J. Ajani,et al.  Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Arsène,et al.  Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Song,et al.  A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  L. Cavanna,et al.  Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC) , 2004 .

[32]  E. Cho,et al.  Epirubicin (E), cisplatin (C) and capecitabine (X) in first-line chemotherapy for patients with advanced gastric cancer , 2004 .

[33]  J. Yook,et al.  A phase I / II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer , 2004 .

[34]  J. Yook,et al.  A phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy , 2004 .

[35]  E. Van Cutsem,et al.  Phase II study of irinotecan + 5FU/FA for patients with previously treated advanced gastric cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Stupp,et al.  Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Kim,et al.  Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer , 2004, British Journal of Cancer.

[38]  Kazuhiro Yoshida,et al.  Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. , 2004, Anticancer research.

[39]  L. A. Wood,et al.  Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists , 2004, British Journal of Cancer.

[40]  B. Ryoo,et al.  A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer , 2004, British Journal of Cancer.

[41]  D. Jaeger,et al.  Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Galle,et al.  214 Safety and efficacy of CPT11/FA/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction , 2003 .

[43]  G. Colucci,et al.  Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). , 2003, Anticancer research.

[44]  F. di Costanzo,et al.  Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  H. Bartelink,et al.  European Code Against Cancer and scientific justification: third version (2003). , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  R. Bugat.  Irinotecan in the treatment of gastric cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Y. Bang,et al.  Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  P. Philip,et al.  Phase II Study of Paclitaxel and Carboplatin in Patients With Advanced Gastric Cancer , 2003, American journal of clinical oncology.

[49]  H. Rosing,et al.  Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  S. Yoshida,et al.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D. Sargent,et al.  A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia , 2002, International journal of gastrointestinal cancer.

[52]  P. Rougier,et al.  Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Yook,et al.  Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  M. Shimada,et al.  [A pilot study of TS-1 combined with cisplatin in patients with advanced gastric cancer]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

[55]  W. Scheithauer,et al.  Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer , 2002, British Journal of Cancer.

[56]  C. Bokemeyer,et al.  Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer , 2002, Anti-cancer drugs.

[57]  R. Kanamaru,et al.  Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer , 2002, Gastric Cancer.

[58]  T. Hickish,et al.  Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  G. Fountzilas,et al.  Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. , 2002, Oncology reports.

[60]  A. Ravaud,et al.  UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. , 2001, European journal of cancer.

[61]  Y. Mok,et al.  Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma , 2001, Cancer.

[62]  E. Van Cutsem,et al.  Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  C. Bokemeyer,et al.  A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer , 2000, British Journal of Cancer.

[64]  R. Herrmann,et al.  Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK). , 1998, European Journal of Cancer.

[65]  I. Judson,et al.  First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial , 1997 .

[66]  U. Haglund,et al.  Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  T. Hickish,et al.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Wils.  The treatment of advanced gastric cancer. , 1996, Seminars in oncology.

[69]  S. Pyrhönen,et al.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. , 1995, British Journal of Cancer.

[70]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.

[71]  D. Shin,et al.  A phase III randomized study of 5‐fluorouracil and cisplatin versus 5‐fluorouracil, doxorubicin, and mitomycin C versus 5‐fluorouracil alone in the treatment of advanced gastric cancer , 1993, Cancer.

[72]  C. Lightdale,et al.  FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Buyse,et al.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.